亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台，協助業界發掘知識產權貿易商機，並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權，或是製造商需要購買技術以提高操作效能，又或是知識產權配套服務供應商，你將會從本網站發掘到有用的知識產權貿易資訊。

返回搜索結果

Dopamine Agonists

總結: Researchers at Purdue University have developed new molecules that fully and selectively activate the dopamine D1 receptor. The compounds derived are useful for treating patients having a dopamine-related dysfunction of the central nervous system (CNS) as well as conditions in which peripheral dopamine receptors are involved. They are expected to be effective against Parkinson's disease, improving cognition, memory, attention deficit hyperactivity disorder, and related developmental disorders.

技術優勢: Lead compound is 50 times more selective for D1 receptors than for D2L receptorsEquipotent, but more selective than other D1 agonists Potentially effective treatment for advanced Parkinson's disease and other CNS disordersOrally bioavailable in animal models

*Background: Dopamine is a neurotransmitter in the central nervous system that has been implicated in numerous neurological disorders. For example, excess stimulation of dopamine may be linked to schizophrenia, whereas either excessive or insufficient functional dopaminergic activity may cause hypertension, narcolepsy, and other disorders including Parkinson's disease. The D1 receptor is a dopamine receptor subtype that may be a viable therapeutic target for dopamine-related pathologies. Accordingly, researchers have directed their efforts to design ligands that are selective D1 receptor agonists.

*Web Links: Purdue Office of Technology CommercializationPurdueInnovation and EntrepreneurshipDavid NicholsPurdue Medicinal Chemistry and Molecular Pharmacology

欲了解更多信息，請點擊這裡